NO20051838L - Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor. - Google Patents

Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.

Info

Publication number
NO20051838L
NO20051838L NO20051838A NO20051838A NO20051838L NO 20051838 L NO20051838 L NO 20051838L NO 20051838 A NO20051838 A NO 20051838A NO 20051838 A NO20051838 A NO 20051838A NO 20051838 L NO20051838 L NO 20051838L
Authority
NO
Norway
Prior art keywords
growth factor
transforming growth
tgf
inhibitor
oxazole compounds
Prior art date
Application number
NO20051838A
Other languages
English (en)
Norwegian (no)
Inventor
Michael John Munchhof
Laura Cook Blomberg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20051838L publication Critical patent/NO20051838L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20051838A 2002-09-18 2005-04-15 Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor. NO20051838L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02
PCT/IB2003/003823 WO2004026863A1 (en) 2002-09-18 2003-09-08 Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
NO20051838L true NO20051838L (no) 2005-04-15

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051838A NO20051838L (no) 2002-09-18 2005-04-15 Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.

Country Status (28)

Country Link
US (1) US7273936B2 (OSRAM)
EP (1) EP1542994B1 (OSRAM)
JP (1) JP4518956B2 (OSRAM)
KR (1) KR20050057415A (OSRAM)
CN (1) CN1681810A (OSRAM)
AP (1) AP2005003261A0 (OSRAM)
AR (1) AR041273A1 (OSRAM)
AT (1) ATE430147T1 (OSRAM)
AU (1) AU2003256003A1 (OSRAM)
BR (1) BR0314383A (OSRAM)
CA (1) CA2499429C (OSRAM)
CO (1) CO5550473A2 (OSRAM)
CR (1) CR7743A (OSRAM)
DE (1) DE60327443D1 (OSRAM)
EA (1) EA200500354A1 (OSRAM)
ES (1) ES2323421T3 (OSRAM)
HR (1) HRP20050250A2 (OSRAM)
IS (1) IS7711A (OSRAM)
MA (1) MA27443A1 (OSRAM)
MX (1) MXPA05002332A (OSRAM)
NO (1) NO20051838L (OSRAM)
OA (1) OA12926A (OSRAM)
PA (1) PA8582701A1 (OSRAM)
PE (1) PE20040987A1 (OSRAM)
PL (1) PL375975A1 (OSRAM)
TW (1) TW200413362A (OSRAM)
UY (1) UY27978A1 (OSRAM)
WO (1) WO2004026863A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
ES2335099T3 (es) * 2002-09-18 2010-03-22 Pfizer Products Inc. Novedosos compuestos de pirazol como inhibidor del factor de crecimiento transformante (tgf).
MXPA05002981A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
AU2005272815A1 (en) * 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of ATP-utilizing enzymes
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
JP2010529031A (ja) * 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害剤としてのナフチリジン誘導体
US8268874B2 (en) 2008-03-03 2012-09-18 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN109045032A (zh) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途
EP4061352A4 (en) 2019-11-19 2024-02-28 Trevena, Inc. Compounds and methods of preparing compounds s1p1 modulators
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
BR9809451A (pt) 1997-05-22 2000-06-20 Searle & Co Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
US6465493B1 (en) * 1999-04-09 2002-10-15 Smithkline Beecham Corporation Triarylimidazoles
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2004517068A (ja) 2000-11-16 2004-06-10 スミスクライン・ビーチャム・コーポレイション 化合物
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
US20040087623A1 (en) 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ グループ リミテッド Tgf阻害剤としてのピラゾール
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003260345A1 (en) 2002-07-31 2004-02-23 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
OA12925A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
ES2335099T3 (es) 2002-09-18 2010-03-22 Pfizer Products Inc. Novedosos compuestos de pirazol como inhibidor del factor de crecimiento transformante (tgf).
MXPA05002981A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
AU2003260810A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors

Also Published As

Publication number Publication date
KR20050057415A (ko) 2005-06-16
JP2006502235A (ja) 2006-01-19
UY27978A1 (es) 2004-04-30
EP1542994B1 (en) 2009-04-29
PL375975A1 (en) 2005-12-12
IS7711A (is) 2005-02-24
US7273936B2 (en) 2007-09-25
CO5550473A2 (es) 2005-08-31
CA2499429A1 (en) 2004-04-01
BR0314383A (pt) 2005-07-19
CN1681810A (zh) 2005-10-12
AU2003256003A1 (en) 2004-04-08
PA8582701A1 (es) 2004-04-23
CR7743A (es) 2005-06-15
MA27443A1 (fr) 2005-07-01
AR041273A1 (es) 2005-05-11
DE60327443D1 (de) 2009-06-10
PE20040987A1 (es) 2004-12-27
EP1542994A1 (en) 2005-06-22
ATE430147T1 (de) 2009-05-15
OA12926A (en) 2006-10-13
ES2323421T3 (es) 2009-07-15
JP4518956B2 (ja) 2010-08-04
EA200500354A1 (ru) 2005-10-27
TW200413362A (en) 2004-08-01
HRP20050250A2 (en) 2005-10-31
WO2004026863A1 (en) 2004-04-01
MXPA05002332A (es) 2005-06-08
AP2005003261A0 (en) 2005-03-31
US20040110797A1 (en) 2004-06-10
WO2004026863A8 (en) 2005-04-21
CA2499429C (en) 2010-09-21

Similar Documents

Publication Publication Date Title
NO20051838L (no) Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
NO20050838L (no) Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
NO20051527L (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
NO20061743L (no) Kinazolinderivater
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
NO981628L (no) (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
WO2003074008A3 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
CA2461622A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
NO951944L (no) Acylerte aminoalkanimidazoler og -triazoler, fremgangsmåte for deres fremstilling, farmasöytisk preparat inneholdende disse og den terapeutiske anvendelse derav